Introduction
Over 30 years ago, Folkman 1 showed that angiogenesis plays a major role in the development and progression of solid cancers. More recently, its function in the development of hematological malignancies has been highlighted. 2, 3 Angiogenesis, as evidenced by an increase in microvascular density (MVD), is increased in the bone marrow of adults with acute myeloid leukemia (AML) and of children with acute lymphoblastic leukemia (ALL). [4] [5] [6] [7] The development of new vessels is thought to be due to overexpression of angiogenic factors, in particular vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF). [8] [9] [10] The plasma VEGF level has been reported to have prognostic significance. 11 VEGF is also thought to be involved in AML blast cell proliferation. These cells express both VEGF and its receptors. 12, 13 VEGF-165 can induce receptor (VEGFR-2) phosphorylation and increase acute leukemia (AL) blast proliferation. VEGF-stimulated endothelial cells secrete granulocyte macrophage colony-stimulating factor, with an impact on AML cell proliferation and survival. 14 However, not all reports on VEGF and b-FGF levels in leukemic patients agree. Some indicate higher bone marrow MVD and higher urinary b-FGF in children with ALL, higher plasma b-FGF in ALL patients and higher plasma b-FGF and VEGF in AML, but not ALL, patients. 7, 15 Others indicate low urinary b-FGF in patients with highly proliferative ALL, high VEGF levels associated with a good prognosis and high VEGF receptor levels associated with a poor prognosis in ALL patients. 16, 17 The mechanism of increase in MVD in the bone marrow of adults with AL thus remains unclear. Several studies suggest that bone marrow stromal cells (BMSCs) derived from stem cells may be involved in the development of leukemia. Stromal cells from AL patients maintain leukemic cells in an immature colony-forming state better than cells from healthy marrow donors do. 18 Stromal cells improve AML and ALL cell viability. 19, 20 To our knowledge, the possible involvement of BMSC in the increase in bone marrow MVD in AL patients has not been investigated. The purpose of this study was to examine the role of BMSC isolated from normal and AL bone marrow in the formation of bone marrow microvessels.
Materials and methods

Patients
Bone marrow samples were obtained from the Hematology Department of Hô tel-Dieu in Paris. In total, 13 samples from leukemic patients (7 AML and 6 ALL) were compared with control samples from 23 leukemic patients in complete remission. The samples were collected with the ethical consent of the patients.
Among the seven AML cases, one case was ALM þ pan myelofibrosis, one was ALM-0, two were ALM-2, two were ALM-3 and one was ALM-5.
Human bone marrow endothelial cell line
Human bone marrow endothelial cell line (HBMEC) was kindly provided by Dr Kenneth J Pienta. Cells were cultured in complete M131 medium (Cascade Biologics, Portland, OR, USA) supplemented with 15% fetal calf serum (FCS), and with microvascular growth supplement (Cascade Biologics) consisting in 1 mg/ml hydrocortisone, 3 ng/ml human b-FGF, 10 mg/ml heparin, 1 ng/ml human epidermal growth factor (EGF) and 0.08 mM dibutyryl-cAMP, 10 mg/ml L-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin (all the supplements are expressed at final concentrations).
Isolation and long-term culture of CD34 (or CD133) bone marrow cells Bone marrow-adherent mononuclear cells (BMMNCs) were obtained by Ficoll density gradient centrifugation as described by Gilmore et al. 21 The monocytes present in the mononuclear cells were discarded by adhesion on plastic Petri plates for 30 min. The non-adherent cells (BMMNCs) were collected and used to isolate the CD34 þ or CD133 þ cell population (with immunomagnetic beads; MACS; Miltenyi Biotec, Paris, France) according to the manufacturer's instructions. The CD34 þ (or CD133 þ ) cells or total unselected BMMNCs were grown for 3 weeks in 0.2% gelatin-coated wells in endothelial cell basal medium MV2 (Promocell, Heidelberg, Germany) supplemented with 1 mg/ml ascorbic acid, 10 ng/ml b-FGF, 5 ng/ml EGF, 20 ng/ ml insulin growth factor-1 (IGF-1), 0.5 ng/ml VEGF and 15% FCS (all the supplements are expressed at final concentrations). Nonadherent cells were discarded after 15 days. The medium was renewed until cell use. Adherent cells were then characterized by immunofluorescence.
Cell characterization by immunofluorescence
Long-term cultured cells were seeded on gelatin-coated LabTeK-chamber slides and allowed to grow. The number of cells and their distribution into specialized cells were determined. The cells were fixed with 4% paraformaldehyde for 2 min at room temperature. Their membranes were permeabilized with 1% Triton X-100 if required (3 min at room temperature). The cells were washed and incubated with primary antibodies against von Willebrand factor (vWF) (Dako, Trappes, France) for endothelial cells, against smooth muscle actin (Dako) for smooth muscle cells and with fibroblast reagent used to deplete with complement cell culture from fibroblasts (specific MAB AS02, an antibody used for detection and elimination of human fibroblast, Dianova (Hamburg, Germany) and distributed by Sera-lab, Loughborough, UK). The cells were then incubated with rhodamine-or fluorescein isothiocyanate)-conjugated antimouse or anti-rabbit IgG antibody (Caltag Laboratories, San Fransisco, CA, USA). Fluorescent staining was analyzed under a Nikon fluorescence microscope (Nikon, France) and by flow cytometry (EPICS XL-MCL; Beckman Coulter, Fullerton, CA, USA).
Effect of the supernatants of cells derived from long-term culture of CD34/CD133 cells on the formation of HBMEC-induced capillary-like structures BMSCs (10 5 ) derived from stem cells were cultured for 18 h in 1 ml of M131 medium without FCS or growth factor in the well of a culture plate. The supernatants were collected. Capillary-like structures were generated using HBMEC as described previously. 22 In brief, growth factor-reduced (GFR) Matrigel (Becton-Dickinson, Le Pont de Claix, France) was thawed on ice and added to 96-well culture plates. The Matrigel was allowed to polymerize for 1-2 h at 37 1C, after which time 100 ml of HBMEC (3.5 Â 10 4 cells per well) in M131 or in BMSC supernatant was seeded on the Matrigelcoated wells. Capillary-like tube formation was observed after 6-h incubation at 37 1C and was quantified by counting the number of cell junctions and tubes in 10 randomly chosen fields using Saisam software (Microvision Instruments, Evry, France).
Capillary-like structure formation of cells derived from long-term culture of CD34/CD133 cells Normal and AL derived from long-term culture of CD34/CD133 cells were seeded on GFR Matrigel as described above to analyze the formation of capillary like structures.
As a control, leukemic cells (i.e., HL 60 cells, human promyelocytic leukemia cells, and K562 cells, an erythroleukemia line) were also tested in the same conditions for their ability to form capillary-like structures on Matrigel.
To identify the cells forming the capillary-like structures, the cells were fixed with 4% formaldehyde for 2 min and then permeabilized with 0.1% Triton X-100 for 1 min. The Matrigel was then washed several times with phosphatebuffered saline containing 10% serum bovine albumin. The cells were labeled with fluorescein-labeled antibody against vWF.
Effect of growth factors and IGF-1 receptor inhibitors on capillary-like structure formation of cells derived from long-term culture of CD34/CD133 cells
The effect of the addition of 500 ng/ml of six cytokines (IGF-1, VEGF-A165, VEGF-C, b-FGF, SDF-1a and EGF) (Promocell) to cells derived from long-term culture of normal bone marrow CD34/CD133 cells, on the formation of the capillary-like structures was tested. The cytokines were added just before plating on Matrigel. After 18-h incubation, the wells were photographed using an inverted light microscope at Â 40 magnification. The effect of inhibitors of IGF-1 (1 mg/ml of a neutralizing goat antibody against IGF-1 receptor (IGF-1R) or 10 mM picropodophyllin, an IGF-1R pathway inhibitor (PPP, Calbiochem, Paris, France)) to cells derived from long-term culture of AL CD34/CD133 cells was tested. The inhibitors were added to cell suspension just before plating cells on Matrigel. The inhibition of capillary-like structure formation was analyzed after 6-and 18-h incubation, as described above.
Quantification of VEGF, b-FGF, IGF-1 and SDF-1a
Cultured BMSCs were carefully washed with phosphatebuffered saline. BMSCs (10 5 ) were then cultured for 18 h in 1 ml of M131 medium containing glutamine but without FCS in the well of a culture plate, after which time the supernatants were collected and tested for cytokine secretion and ability to generate HBMEC capillary-like structure formation on GFR Matrigel, as described above. IGF-1, VEGF165, b-FGF and SDF-1 were quantified using commercial kits (Quantikine; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions for cell culture supernatants. The results were expressed in picograms per milliliter. Determination of signaling pathways involved in the formation of capillary-like structures by long-term culture of AL CD34-derived cells
To elucidate the mechanism of formation of capillarylike structures on Matrigel with AL-derived long-term culture of CD34-derived cells or with IGF-1-treated long-term culture of normal CD34-derived cells, we tested the effect of six signaling inhibitors, including five inhibitors of Ras signaling (wortmannin (a PI3 kinase inhibitor), UO 126 (a MEK-1/2 kinase inhibitor), PD 98059 (an Erk inhibitor), rapamycin (a raptor-mTor complex inhibitor) and FTI-277 (a farnesyl transferase inhibitor)) and one inhibitor of Rho GTPase (GGTI-298 (geranyl-geranyl transferase inhibitor)). All inhibitors were from Calbiochem and were used at a final concentration of 10 mM added to the BMSC suspension just before plating on Matrigel. The cells were examined after 6-h incubation.
Statistical analysis
Results are expressed as means±standard error of the mean (s.d.) and compared using a two-tailed non-parametric MannWhitney test (InStat software; Sigma, Quentin-Fallavier, France). A P-value o0.05 was considered significant. 
Results
Identification and distribution of adherent cells obtained after long-term culture of CD34 þ or CD133 þ cells
In the long-term culture, the number and distribution of adherent cells derived from CD34 þ stem cells were CD45À, allowing us to consider that the cells are not hematopoietic cells. They were identical in the AL and control groups (Table 1) 
Pro-angiogenic effect of BMSC supernatants BMSC supernatants from AML and ALL patients induced an increase in the number and length of capillary-like structures formed by HBMEC as compared with BMSC supernatants from normal stem cells or controls without supernatant ( Figure 1 ). There were no differences according to the origin of the BMSC (CD34 þ , CD133 þ or all BMMNCs) (results not shown).
Formation of capillary-like structures on Matrigel by BMSC ('vasculogenic mimicry')
Normal BMSCs plated on Matrigel were unable to form capillary-like structures. On the other hand, BMSCs derived from AML stem cells spontaneously generated capillary-like structures regardless of the origin of the stromal cells (CD34 þ , CD133 þ cells or all BMMNCs) (Figure 2) . Similar results were obtained with BMSCs derived from ALL stem cells (not shown). Immunocytochemistry revealed that elongated endothelial cells (labeled with anti-vWF) made up only 7% of the cells included in these structures (Figure 3) . It was concluded that other BMSCs have also been incorporated. The round cells expressing vWF and located outside the capillary-like structures may be immature endothelial cells. The BMSC capillary network in AL is thus a mosaic containing both endothelial and nonendothelial cells. The generation of microvascular channels by genetically deregulated, aggressive tumor cells has been termed 'vasculogenic mimicry. ' We showed that leukemic cell lines (HL60 and K532) seeded on Matrigel, with or without growth factors, were unable to form tubes (results not shown).
Angiogenic cytokines secreted by BMSC
Angiogenic cytokines secreted by AL-derived and normal BMSCs were quantified to identify those that accounted for the increase in HBMEC-induced capillary tube formation. There Bone marrow stromal cells anomaly in acute leukemia P Mirshahi et al were no differences in VEGF and b-FGF levels in the BMSC supernatants from AML and controls (Table 2) . Moreover, VEGF levels were lower in ALL-derived BMSC supernatants than in controls. SDF-1a levels were higher in the BMSC supernatants of ALL and AML than in controls.
A greater number of BMSC samples derived from leukemic stem cells secreted a higher level of IGF (4100 pg/ml per 1 Â 10 5 cells) than BMSC samples (n ¼ 7) derived from normal bone marrow cells (o100 pg/ml per 1 Â 10 5 cells BMSC) (Figure 4 ).
Mechanisms involved in vasculogenic mimicry
To identify the factors that might be responsible for vasculogenic mimicry by AL-derived BMSC, the effect of adding various cytokines to normal BMSC on tube formation was tested. IGF-1 induced vasculogenic mimicry, SDF-1a had a slight effect, whereas VEGF-A, VEGF-C, EGF and b-FGF were inactive ( Figure 5 ). Vasculogenic mimicry was inhibited by the addition to AL-derived BMSC of a neutralizing antibody against IGF-1R or of PPP (an inhibitor of IGF-1R), thus suggesting that IGF-1R is involved in BMSC vasculogenesis ( Figure 6 ).
To understand the molecular mechanisms involved in vasculogenic mimicry, the effect of inhibitors of signaling pathways on capillary tube formation was tested using AL-derived BMSC or IGF-1-treated normal BMSC. Tube formation was inhibited by GGTI-298 (inhibitor of Rho GTPases) (68 ± 6% inhibition, Po0.0001) and by wortmannin (inhibitor of PI3 kinase) (92±8% inhibition, Po0.0001) but not by FTI-277 (an inhibitor of farnesyl transferase) (Figure 7) nor by the three other tested inhibitors UO 126 (MEK-1/2 kinase inhibitor), PD 98059 (Erk inhibitor) and rapamycin (raptor-mTor complex inhibitor) (results not shown).
Discussion
We showed that cells obtained from long-term culture of CD34 þ (or CD133 þ ) cells isolated from normal and AL bone marrow in a selective medium, were differentiated into endothelial cells, fibroblasts, smooth muscle cells and unidentified cells. All the cells are CD45À, and therefore are not hematopoietic cells. Thus, we consider that all cells obtained in long-term culture are BMSCs. The number of BMSCs and their distribution among these cell types were similar in normal and AL-derived BMSC. However, functional differences were observed between the normal and AL-derived BMSCs, which might explain the increase in MVD in the bone marrow of AL patients. In contrast to normal BMSCs, all the BMSCs from AL patients are involved in the formation of a mosaic of microvessels that is lined with both stromal and endothelial cells, a process called 'vasculogenic mimicry. ' We have also shown that IGF-1, which is overexpressed in leukemic stromal cells, could account for their formation as this formation was prevented by several IGF inhibitors.
In addition, we showed that HL60 and K562 cells, which secrete large amounts of IGF-1, 23 are unable to form tubular network on Matrigel in the same conditions. The increase in MVD observed in AL might occur through two mechanisms:
(i) The first mechanism relates to the observed higher angiogenic activity of AL-derived BMSCs than normal BMSCs on human bone marrow endothelial cells. AL-derived BMSC supernatants were more effective than normal BMSC supernatants in inducing capillary tube formation with HBMEC seeded on Matrigel. (HBMECs were used to account for endothelial cell tissue specificity.)
The greater efficacy could have been due to the secretion of cytokines that are positive regulators of angiogenesis by the AL-derived BMSC. VEGF and b-FGF were not involved as their levels were similar in culture medium from normal and AML-derived BMSC. VEGF levels secreted by ALLderived BMSCs were even lower than in controls. On the other hand, SDF-1a and IGF-1 levels were higher in the culture medium of AL-derived BMSCs than normal BMSCs. Both SDF-1a and IGF-1 could thus have contributed to the increase in capillary tube formation. SDF-1a is an angiogenic factor. 24 It induces an enhanced connection between embryonic stem cells and thus increases their ability to assemble in a reticular network. 25 SDF-1a also increases vasculogenesis as it was described that SDF-1a recruits vascular progenitors to neovasculature: SDF-1a is necessary and sufficient to incorporate marrow-derived precursors into tumor endothelium. 26 IGF-1 protects endothelial cells through the PI3/Akt pathway and is thus associated with hyperangiogenesis. 27 However, the contribution of other angiogenic factors not determined in this study cannot be excluded.
(ii) The second mechanism relates to the inclusion of all ALderived BMSCs in the capillary-like tubes formed on Matrigel ('vasculogenic mimicry'). Only AL-derived BMSCs but not normal BMSCs were able to form capillary tubes, and only 7% of endothelial cells expressing vWF-related antigen were incorporated, indicating that the capillary network formed by AL-derived BMSCs was a mosaic containing both endothelial cells and other BMSCs. The difference between normal and AL-derived BMSCs was not related to any imbalance in the proportion of stromal cell types (i.e., endothelial cells, fibroblasts and smooth muscle cells). CD34/CD133 cells from AL patients would thus seem to be able to direct stromal cell dysfunction. CD133/34 þ cells isolated from bone marrow of patients with AL probably did not participate in capillary tube formation as it has been shown that AML blasts grown for either 1 or 2 weeks under endothelial cell culture conditions failed to form tubes on Matrigel. 28 In addition, we also showed that leukemic cells (HL60 and K562) were unable to form capillary-like structures on Matrigel.
Normal BMSCs plated on Matrigel did not form a vascular-like network, and the addition of several cytokines involved in angiogenesis (VEGF-A, VEGF-C, EGF and b-FGF) did not induce vasculogenic mimicry. On the other hand, the addition of SDF-1a, which is secreted in larger amounts by AL-derived BMSCs than by normal BMSCs, had no effect. In contrast, IGF-1 synthesized by AL-derived BMSCs added to normal BMSCs induces tube formation of all normal BMSCs and would thus appear to be involved in vasculogenic mimicry. This was confirmed by the observation that the process was prevented by a neutralizing antibody against IGF-1R and a potent IGF-1R inhibitor (PPP). The signaling pathways responsible for the vasculogenic mimicry present with AL-derived BMSC or induced by IGF-1 in normal BMSC were dependent on Rho GTPase and PI3 kinase activation as vasculogenic mimicry was prevented by their inhibitors (by 68 and 92%, respectively). These results agree with the observation that GTPases and PI3 kinase are critical for Schwann cell motility by IGF-1. 29 The process of vasculogenic mimicry has already been described in tumor neovascularization. Tumor cells participate in the generation of functional capillary-like tubes as they have been found to line the tubes. 30, 31 In some cancers, vasculogenic mimicry is associated with high tumor grade, invasion and metastasis. 32 Aggressive uveal melanoma cells can also generate vascular-like channels without the involvement of endothelial cells. 33 Vasculogenic mimicry contributes to blood delivery to tumors as the tubes are connected to regular blood vessels. Vasculogenic mimicry in patients with leukemia differs from bone marrow macrophage-induced vasculogenic mimicry in patients with multiple myeloma. In multiple myeloma, vasculogenic mimicry seems to be related to VEGF and b-FGF action on multiple myeloma macrophages, which acquire endothelial cell markers and form capillary-like structures. 34 In AL, vasculogenic mimicry depends neither on VEGF nor on b-FGF. In addition, the BMSCs involved do not acquire endothelial cell markers as they do not express vWF. Our results may thus explain why treatments targeting endothelial cells, such as monoclonal antibodies against VEGF-A (bevacizumab), are ineffective in patients with refractory leukemia. 35 However, we did not investigate whether capillary-like channels could contribute to the blood supply. In contrast, it might be worthwhile testing Rho blockers as they inhibit vasculogenic mimicry and angiogenesis. 36, 37 
